Publications and Presentations
Bispecific antibodies are an important and growing segment in antibody therapeutics, particularly in the immuno-oncology space. Manufacturing of a bispecific antibody with…
The humanization of animal model immune systems by genetic engineering has shown great promise for antibody discovery, tolerance studies and for the evaluation of vaccines…
Most of the approved monoclonal antibodies used in the clinic were initially discovered in mice. However, many targets of therapeutic interest are highly conserved…
Expression of human lambda expands the repertoire of OmniChickens Read More »
Bovine antibodies are unusual in having exceptionally long heavy chain CDR3 regions, with an average length of 25 amino acids, and an ‘ultralong’ subset that can reach >70 amino acids in length…
OmniTaur™: Ultralong CDR3 cow antibodies for challenging targets Read More »
Monoclonal antibodies (mAbs) for therapeutic applications should be as similar to native human antibodies as possible to minimize their immunogenicity in patients…
Targeting the CD47-signal-regulatory protein α (SIRPα) pathway represents a novel therapeutic approach to enhance anti-cancer immunity by promoting both innate and…
The unique characteristics of the avian embryo, with its large opaque yolk, have necessitated the development of different approaches to transgenesis from…
Production of Transgenic Chickens Using Cultured Primordial Germ Cells and Gonocytes. Read More »
Transgenic animal platforms for the discovery of human monoclonal antibodies have been developed in mice, rats, rabbits and cows. The immune response to human proteins…
An important characteristic of chickens is that the antibody repertoire is based on a single framework, with diversity found mainly in the CDRs of the light and heavy chain…
